Acute plasma amylase increase after glucagon-like peptide-1 receptor agonist exenatide administration in Type 2 diabetes

被引：3
|
作者：
Smits, M. M. [1 ]
Tonneijck, L. [1 ]
Muskiet, M. H. A. [1 ]
Diamant, M. [1 ]
Kramer, M. H. H. [1 ]
Cahen, D. L. [2 ]
van Raalte, D. H. [1 ]
机构：
[1] Vrije Univ Amsterdam Med Ctr, Diabet Ctr, Dept Internal Med, Amsterdam, Netherlands
[2] Erasmus Univ, Dept Gastroenterol & Hepatol, Med Ctr, Rotterdam, Netherlands
来源：
DIABETIC MEDICINE | 2017年 / 34卷 / 04期
关键词：
SECRETION; LIPASE;
D O I：
10.1111/dme.13160
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
下载
收藏
页码：591 / 592
页数：2
相关论文
共 50 条
  • [1] Glucagon-like peptide-1 receptor agonist exenatide can induce hypothermia
    Shen, Yunfeng
    Zhu, Hongyan
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2016, 32 (SUPP 2) : 41 - 42
  • [2] Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide
    van Genugten, Renate E.
    van Raalte, Daniel H.
    Diamant, Michaela
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2009, 86 : S26 - S34
  • [3] Initiating a Glucagon-like Peptide-1 Receptor Agonist in the Management of Type 2 Diabetes Mellitus
    Gavin, James R., III
    JOURNAL OF THE AMERICAN OSTEOPATHIC ASSOCIATION, 2012, 112 (01): : S16 - S21
  • [4] Glucagon-like peptide-1 receptor agonist prescribing patterns in adolescents with type 2 diabetes
    Bensignor, Megan O.
    Wolf, Jack M.
    Rudser, Kyle D.
    Kelly, Aaron S.
    Arslanian, Silva
    DIABETES OBESITY & METABOLISM, 2022, 24 (07): : 1380 - 1384
  • [5] The development of non-peptide glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes
    Moon, Ho-Sang
    Kim, Mi-Kyung
    Son, Moon-Ho
    ARCHIVES OF PHARMACAL RESEARCH, 2011, 34 (07) : 1041 - 1043
  • [6] The development of non-peptide glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes
    Ho-Sang Moon
    Mi-Kyung Kim
    Moon-Ho Son
    Archives of Pharmacal Research, 2011, 34 : 1041 - 1043
  • [7] TREATMENT WITH A GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST EXENATIDE DECREASES ALBUMINURIA IN OVERWEIGHT TYPE 2 DIABETIC PATIENTS
    Bulum, Tomislav
    Prkacin, Ingrid
    Duvnjak, Lea
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2016, 31 : 1487 - 1487
  • [8] Glucagon-like Peptide-1 Receptor Agonist Use in Patients With Liver Cirrhosis and Type 2 Diabetes
    Yen, Fu-Shun
    Hou, Ming-Chih
    Wei, James Cheng-Chung
    Shih, Ying-Hsiu
    Hsu, Chung Y.
    Hsu, Chih-Cheng
    Hwu, Chii-Min
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2024, 22 (06) : 1255 - 1264.e18
  • [9] Renal Function Improvement With Glucagon-Like Peptide-1 Receptor Agonist in a Patient With Type 2 Diabetes
    Yanai, Hidekatsu
    JOURNAL OF MEDICAL CASES, 2024, 15 (2-3) : 37 - 42
  • [10] Acute effects of the glucagon-like peptide-1 receptor agonist, exenatide, on blood pressure and heart rate responses to intraduodenal glucose infusion in type 2 diabetes
    Thazhath, Sony S.
    Marathe, Chinmay S.
    Wu, Tongzhi
    Chang, Jessica
    Khoo, Joan
    Kuo, Paul
    Checklin, Helen L.
    Bound, Michelle J.
    Rigda, Rachael S.
    Horowitz, Michael
    Jones, Karen L.
    Rayner, Christopher K.
    DIABETES & VASCULAR DISEASE RESEARCH, 2017, 14 (01): : 59 - 63
12345